Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum GFAP and UCH-L1 Levels for the Assessment of the Absence of Hemorrhagic Transformation: A Multicenter Prospective Cohort Study.
Guo ZN, Qu Y, Abuduxukuer R, Jin H, Zhang P, Wang J, Zhang KJ, Qi S, Zheng XY, Zhang Y, Gao JH, Pan DW, Liu XD, Li CY, Chen LP, Chen JH, Gu JL, Wang AY, Jiang L, Liu L, Jiang Y, Wang CF, Jia Y, Xin H, Jiang CL, Qi YB, Hu XF, Li S, Sun X, Nguyen TN, Yang Y; Biomarkers of Brain Injury Investigator Study Group. Guo ZN, et al. Among authors: jia y. Stroke. 2025 Jan;56(1):22-29. doi: 10.1161/STROKEAHA.124.047887. Epub 2024 Dec 9. Stroke. 2025. PMID: 39648906
Comparison of thrombopoietin receptor agonists plus recombinant human thrombopoietin vs. recombinant human thrombopoietin alone for hematopoietic reconstruction in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.
Wang F, Xu X, Yang R, Jia Y, Gao G, Huang T, He A. Wang F, et al. Among authors: jia y. Transplant Cell Ther. 2024 Dec 21:S2666-6367(24)00834-0. doi: 10.1016/j.jtct.2024.12.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39716625
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.
Zhong J, Fei K, Wu L, Li B, Wang Z, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu AW, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Yao S, Yu J, Cai SL, Cai Y, Xu J, Zhuang W, Luo X, Duan J, Wang J. Zhong J, et al. Among authors: jia y. Signal Transduct Target Ther. 2024 Dec 24;9(1):369. doi: 10.1038/s41392-024-02087-6. Signal Transduct Target Ther. 2024. PMID: 39715755 Free PMC article. Clinical Trial.
12,160 results
You have reached the last available page of results. Please see the User Guide for more information.